GOVX Geovax Labs Inc
GeoVax Labs Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
Company profile
Ticker
GOVX
Exchange
Website
CEO
David A. Dodd
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Dauphin Technology Inc
SEC CIK
Corporate docs
IRS number
870455038
GOVX stock data
()
Investment data
Securities sold
Number of investors
Calendar
7 Nov 19
19 Jan 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 333.21K | 209.94K | 364.23K | 299.3K | |
| Net income | -424.43K | -654.15K | -701.45K | -634.35K | |
| Diluted EPS | -0.03 | -1.01 | -1.43 | 6.41 | |
| Net profit margin | -127% | -312% | -193% | -212% | |
| Operating income | -425.94K | -653.94K | -701.55K | -634.33K | |
| Net change in cash | 352.95K | 40.43K | -83.72K | -251.54K | |
| Cash on hand | 569.36K | 216.41K | 175.99K | 259.7K |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 963.2K | 1.08M | 828.92K | ||
| Net income | -2.56M | -2.17M | -3.27M | -2.69M | |
| Diluted EPS | -0.02 | -0.03 | -0.08 | -0.08 | |
| Net profit margin | -266% | -202% | -395% | ||
| Operating income | -2.56M | -2.17M | -3.27M | -2.69M | |
| Net change in cash | -53.03K | -141.3K | -606.32K | -41.3K | |
| Cash on hand | 259.7K | 312.73K | 454.03K | 1.06M |
Financial data from Geovax Labs earnings reports
Institutional ownership Q3 2019
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 1 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | NaN |
Largest owners |
Shares | Value |
|---|---|---|
| Quad-Cities Investment | 1 | $0 |
Financial report summary
?Competition
Bristol Myers Squibb • Pfizer • Medimmune • AstraZeneca • Novavax • Protein Sciences • Advaxis • Sanofi • NewLink Genetics • Glaxosmithkline
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
arm, bid, buying, calculation, calendar, compliance, consecutive, deliver, difficult, fulfill, insufficient, issuer, marketplace, moving, notified, November, OTC, OTCQB, pay, Pink, purpose, regain, remedial, removed, stockholder, timeframe, unable, unissued
Removed:
banking, exercised, joint
Financial reports
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
13 May 19
10-K/A
2018 FY
Annual report (amended)
12 Apr 19
10-K
2018 FY
Annual report
26 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 FY
Annual report
23 Mar 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
Current reports
8-K
Submission of Matters to a Vote of Security Holders
3 Jan 20
8-K
Other Events
15 Nov 19
8-K
GeoVax Reports 2019 Third Quarter Financial Results
7 Nov 19
8-K
Other Events
1 Nov 19
8-K
Other Events
18 Oct 19
8-K
Changes in Registrant's Certifying Accountant
7 Oct 19
8-K
Other Events
1 Oct 19
8-K
GeoVax Reports 2019 Second Quarter Financial Results
14 Aug 19
8-K
GeoVax Issues Shareholder Update Letter
2 Aug 19
8-K
Entry into a Material Definitive Agreement
24 Jul 19
Registration and prospectus
D/A
$3.26M in equity, sold $3.26M, 2 investors
1 Nov 19
D/A
$700K in equity, sold $700K, 2 investors
1 Nov 19
D
$700K in equity, sold $700K, 2 investors
1 Nov 19
D
$3.26M in equity / options, sold $3.26M, 2 investors
31 Oct 19
424B3
Prospectus supplement
8 Nov 18
424B3
Prospectus supplement
7 Aug 18
424B3
Prospectus supplement
3 May 18
424B1
Prospectus with pricing info
3 Apr 18
POS AM
2017 FY
Prospectus update (post-effective amendment)
23 Mar 18
424B3
Prospectus supplement
9 Nov 17
Proxies
DEF 14A
Definitive proxy
2 Dec 19
PRE 14A
Preliminary proxy
21 Nov 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
1 Mar 19
PRER14A
Preliminary revised proxy
27 Feb 19
PRE 14A
Preliminary proxy
19 Feb 19
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
27 Apr 18
DEF 14A
Definitive proxy
16 Jun 17
Other
EFFECT
Notice of effectiveness
2 Apr 18
EFFECT
Notice of effectiveness
3 Apr 17
EFFECT
Notice of effectiveness
6 Apr 16
CORRESP
Correspondence with SEC
4 Apr 16
CORRESP
Correspondence with SEC
4 Apr 16
UPLOAD
Letter from SEC
31 Mar 16
EFFECT
Notice of effectiveness
30 Mar 16
EFFECT
Notice of effectiveness
30 Mar 16
EFFECT
Notice of effectiveness
30 Dec 15
EFFECT
Notice of effectiveness
10 Sep 15
Ownership
SC 13G/A
GeoVax Labs, Inc.
2 Jan 19
SC 13D/A
GeoVax Labs, Inc.
29 Mar 18
SC 13G/A
GeoVax Labs, Inc.
4 Jan 18
SC 13D/A
GeoVax Labs, Inc.
9 Nov 17
SC 13D/A
GeoVax Labs, Inc.
13 Jul 17
SC 13D/A
GeoVax Labs, Inc.
5 Jan 17
SC 13G/A
GeoVax Labs, Inc.
5 Jan 17
SC 13D/A
GeoVax Labs, Inc.
23 Aug 16
SC 13D/A
GeoVax Labs, Inc.
4 Apr 16
SC 13G/A
GeoVax Labs, Inc.
5 Jan 16